[go: up one dir, main page]

MX2021000348A - 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo. - Google Patents

2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo.

Info

Publication number
MX2021000348A
MX2021000348A MX2021000348A MX2021000348A MX2021000348A MX 2021000348 A MX2021000348 A MX 2021000348A MX 2021000348 A MX2021000348 A MX 2021000348A MX 2021000348 A MX2021000348 A MX 2021000348A MX 2021000348 A MX2021000348 A MX 2021000348A
Authority
MX
Mexico
Prior art keywords
fluoro
crystalline
nitrotoluene
preparation
formula
Prior art date
Application number
MX2021000348A
Other languages
English (en)
Inventor
Elena Brasola
Silvestro Marco Di
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2021000348A publication Critical patent/MX2021000348A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/07—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms
    • C07C205/11—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings
    • C07C205/12—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings the six-membered aromatic ring or a condensed ring system containing that ring being substituted by halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06—Preparation of nitro compounds
    • C07C201/16—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto 2-fluoro-3-nitrotolueno cristalino de fórmula (I): (ver Fórmula) y un procedimiento para la preparación del mismo. Además, la presente invención se refiere a un procedimiento para la síntesis de un compuesto de fórmula (II): (ver Fórmula) o sales del mismo por medio del 2-fluoro-3-nitrotolueno cristalino.
MX2021000348A 2018-07-09 2019-07-03 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo. MX2021000348A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18182368.3A EP3594199B1 (en) 2018-07-09 2018-07-09 Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof
PCT/EP2019/067894 WO2020011626A1 (en) 2018-07-09 2019-07-03 Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof

Publications (1)

Publication Number Publication Date
MX2021000348A true MX2021000348A (es) 2021-06-08

Family

ID=62904314

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000348A MX2021000348A (es) 2018-07-09 2019-07-03 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo.

Country Status (17)

Country Link
US (2) US12162815B2 (es)
EP (1) EP3594199B1 (es)
JP (1) JP7407166B2 (es)
CN (1) CN112654602B (es)
AU (1) AU2019303323B2 (es)
CA (1) CA3105559A1 (es)
CY (1) CY1123514T1 (es)
DK (1) DK3594199T3 (es)
ES (1) ES2815899T3 (es)
HR (1) HRP20201198T1 (es)
HU (1) HUE052049T2 (es)
LT (1) LT3594199T (es)
MX (1) MX2021000348A (es)
PL (1) PL3594199T3 (es)
PT (1) PT3594199T (es)
SI (1) SI3594199T1 (es)
WO (1) WO2020011626A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552404A (en) 2004-06-17 2010-04-30 Cytokinetics Inc Compounds, compositions and methods
EP2968173B1 (en) 2013-03-14 2020-10-14 Amgen Inc. Heterocyclic compounds and their uses
AU2018290983B2 (en) 2017-06-30 2023-11-23 Amgen Inc. Methods of treating heart failure with cardiac sarcomere activators
EP4265597A3 (en) 2017-06-30 2023-11-22 Amgen Inc. Synthesis of omecamtiv mecarbil
IL272573B2 (en) 2017-09-13 2023-10-01 Amgen Inc Sarcomere activating bisamide compounds and their uses
WO2020037164A1 (en) 2018-08-17 2020-02-20 Amgen Inc. Salts and crystal forms of omecamtiv mecarbil
US12442027B2 (en) 2018-12-18 2025-10-14 Amgen Inc. Method of reducing aromatic nitro compounds
MX2023005455A (es) 2020-11-12 2023-07-27 Amgen Inc Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
US11702380B2 (en) 2021-03-10 2023-07-18 Amgen Inc. Synthesis of omecamtiv mecarbil
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552404A (en) 2004-06-17 2010-04-30 Cytokinetics Inc Compounds, compositions and methods
WO2007070683A2 (en) 2005-12-15 2007-06-21 Cytokinetics, Inc. Certain chemical entities, compositions and methods
AR059339A1 (es) * 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
CN101177400A (zh) 2006-11-06 2008-05-14 吕铁环 一种生产2-氟-3-硝基甲苯的方法
KR101511396B1 (ko) 2007-07-20 2015-04-13 추가이 세이야쿠 가부시키가이샤 ｐ27 단백질 유도제
TWI648274B (zh) * 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類 （二）
MX2015012416A (es) 2013-03-14 2016-04-07 Amgen Inc Compuestos heterociclicos y sus usos.
EP2968173B1 (en) 2013-03-14 2020-10-14 Amgen Inc. Heterocyclic compounds and their uses
WO2016123291A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
WO2016210240A1 (en) 2015-06-26 2016-12-29 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
EP3266773B1 (en) * 2016-07-04 2018-04-11 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of lapatinib ditosylate monohydrate by means of an improved crystallization procedure
EP4265597A3 (en) 2017-06-30 2023-11-22 Amgen Inc. Synthesis of omecamtiv mecarbil
AU2018290983B2 (en) 2017-06-30 2023-11-23 Amgen Inc. Methods of treating heart failure with cardiac sarcomere activators
WO2020037164A1 (en) 2018-08-17 2020-02-20 Amgen Inc. Salts and crystal forms of omecamtiv mecarbil
US12442027B2 (en) 2018-12-18 2025-10-14 Amgen Inc. Method of reducing aromatic nitro compounds
AU2021221106A1 (en) 2020-02-10 2022-09-22 Amgen Inc. Omecamtiv mecarbil tablet
MX2023005455A (es) 2020-11-12 2023-07-27 Amgen Inc Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
US11702380B2 (en) 2021-03-10 2023-07-18 Amgen Inc. Synthesis of omecamtiv mecarbil

Also Published As

Publication number Publication date
AU2019303323B2 (en) 2024-08-22
ES2815899T3 (es) 2021-03-31
DK3594199T3 (da) 2020-09-14
EP3594199A1 (en) 2020-01-15
CA3105559A1 (en) 2020-01-16
PT3594199T (pt) 2020-09-04
EP3594199B1 (en) 2020-07-01
CN112654602B (zh) 2025-05-16
US20250179005A1 (en) 2025-06-05
JP2021532076A (ja) 2021-11-25
LT3594199T (lt) 2020-11-10
AU2019303323A1 (en) 2021-01-28
HUE052049T2 (hu) 2021-04-28
PL3594199T3 (pl) 2020-11-16
CN112654602A (zh) 2021-04-13
SI3594199T1 (sl) 2020-10-30
HRP20201198T1 (hr) 2020-11-13
JP7407166B2 (ja) 2023-12-28
US12162815B2 (en) 2024-12-10
WO2020011626A1 (en) 2020-01-16
CY1123514T1 (el) 2022-03-24
US20210292271A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
MX2021000348A (es) 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo.
PH12020500673A1 (en) Compounds
PH12022551574A1 (en) Egfr inhibitors
ZA202000411B (en) Polymorphs of 5-fluoro-4-imino-3-methyl-1-tosyl-3,4-dihydropyrimidin-2-one
ZA202201503B (en) Urea compound for antagonizing lpa1 receptor
MX2021008002A (es) Sales nuevas y forma polimorfica del acido bempedoico.
AR116790A1 (es) PROCEDIMIENTO PARA LA PREPARACIÓN DE 3a-HIDROXI-5a-PREGNAN-20-ONA (BREXANOLONA)
EP4410773A3 (en) Process for the synthesis of (s) 3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid
MX2017017022A (es) Metodo para la sintesis de derivados de rapamicina.
CR20240014A (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
PH12020500128A1 (en) Inhibitors of ror gamma
GEAP202215389A (en) Polymorphs
MX2022009281A (es) Inhibidores de rorgamma.
WO2020127208A8 (en) Pharmaceutical process and intermediates
MX2021001904A (es) Formas solidas de benzoxaborol sustituido y composiciones de las mismas.
MX2019001228A (es) Metodo de produccion del compuesto de pirazol-amida.
MX2023000970A (es) Metodo de preparacion de aminofuranos.
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
SA520412408B1 (ar) عملية تحضير مركبات ثنائي أريل أوكسي بنزو ديازول غير متجانسة مزدوجة الاستبدال
PH12018500999A1 (en) Sodium channel blocker
MX2021006692A (es) Proceso mejorado para preparar ozanimod.
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
MX2021012690A (es) Formas cristalinas y metodos para producir formas cristalinas de un compuesto.
PH12022550529A1 (en) Magl inhibitor, preparation method and use thereof
MX2022000651A (es) Proceso mejorado para preparar ozanimod.